18F-DPA-714 PET/MR in Dysfunctional Brain Diseases

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06851143

Enrollment

Registered

2025-02-28

Start date

2025-03-01

Completion date

2027-12-31

Last updated

2025-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Disease

Keywords

18F-DPA-714 PET/MR, cognitive impairment, dyskinesia, Disorders of consciousness, Autoimmune encephalitis

Brief summary

This is a diagnostic pilot study that recruited 25 normal volunteers and 40 patients with dysfunctional brain diseases and performed 18F-DPA-714 PET/MR imaging to evaluate the correlation between the multimodal imaging features of dysfunctional brain diseases, to explore the potential pathological mechanisms of neuroimmune activation, and to further analyse the value of PET/MR-based multimodal imaging in the diagnosis and differential diagnosis of dysfunctional brain diseases. and further analyse the diagnostic and differential diagnostic value of PET/MR-based multimodal imaging in dysfunctional brain diseases.

Interventions

DIAGNOSTIC_TEST18F-DPA-714 PET/MR scan

Saline intravenous solution of 18F-DPA-714 administered at 0.1 mCi/kg by bodyweight

Study design

Allocation

Intervention model

SEQUENTIAL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Dysfunctional disorders diagnosed according to the guidelines include: cognitive disorders, movement disorders, disorders of consciousness-like disorders, and autoimmune encephalitis. Signing the PET/MR informed consent form to volunteer for this study

Exclusion criteria

* Minors, pregnant women, nursing mothers, those with severe liver or kidney insufficiency, history of allergy to contrast media or other drugs. Diagnosis of viral encephalitis, acute myelitis, idiopathic epilepsy, antibody-negative AIE; diagnosis of any major disease; history of alcohol or drug abuse/dependence; history of cardiorespiratory disease, oncology, haematological disorders, poorly controlled chronic diseases; contraindications to PET/MR examination. History of head trauma, history of surgery. History of other neurological disorders.

Design outcomes

Primary

Measure	Time frame
Maximum Standardized uptake value (SUVmax)	1 day from injection of the tracer

Contacts

Primary ContactYing Guo Ying Guo

guoying01192022@163.com0086+15991459177

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026